Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274690 · ClinicalTrials.gov registry record · Phase 2
Post-Operative Nausea And Vomiting Study In Female Patients
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 435
- Enrollment target
NCT00274690 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 435 participants.
The verdict
NCT00274690, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 435 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine an effective dose of this NK-1 anti-emetic medication to prevent nausea and vomiting in females after surgery.
Interventions
- DRUG GW679769
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 435 participants |
| Start Date | 2005-02 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00274690
The ClinicalTrials.gov registry entry for NCT00274690 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 435 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GW679769 is the first listed.
NCT00274690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00274690 about?
NCT00274690 is a clinical study titled "Post-Operative Nausea And Vomiting Study In Female Patients". The primary purpose of this study is to determine an effective dose of this NK-1 anti-emetic medication to prevent nausea and vomiting in females after surgery.
What is the current status of trial NCT00274690?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 435 participants. The study started on 2005-02. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00274690?
The interventions under investigation include: GW679769 (DRUG).
Who is sponsoring clinical trial NCT00274690?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.